Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Operating Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Operating Expenses for 17 consecutive years, with $152.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 19.74% to $152.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $963.8 million, a 35.96% increase, with the full-year FY2025 number at $963.8 million, up 35.96% from a year prior.
  • Operating Expenses was $152.5 million for Q4 2025 at Myriad Genetics, down from $167.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $481.0 million in Q2 2025 to a low of -$8.2 million in Q4 2023.
  • A 5-year average of $197.3 million and a median of $193.8 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 129.29% in 2023, then surged 2417.07% in 2024.
  • Myriad Genetics' Operating Expenses stood at $203.9 million in 2021, then tumbled by 86.27% to $28.0 million in 2022, then plummeted by 129.29% to -$8.2 million in 2023, then soared by 2417.07% to $190.0 million in 2024, then dropped by 19.74% to $152.5 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Operating Expenses are $152.5 million (Q4 2025), $167.1 million (Q3 2025), and $481.0 million (Q2 2025).